



March 1<sup>st</sup>, 2021

PeptiDream Inc.

<https://www.peptidream.com>

Ticker Code : 4587 TSE First Section

## **PeptiDream Announces Licensing of Automated PDPS Platform to Ono Pharmaceutical**

KANAGAWA, JAPAN – March 1<sup>st</sup>, 2021 – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(Tokyo:4587) today announced that it has entered into a Technology License Agreement with Osaka-based Ono Pharmaceutical Co., Ltd., (“ONO”), to non-exclusively license PeptiDream’s proprietary automated Peptide Discovery Platform System (PDPS) technology platform to ONO.

Under the terms of the agreement, PeptiDream will receive an undisclosed upfront payment, as well as be eligible for certain payments based on achievement of certain predetermined development milestones for any constrained peptides and/or small molecules discovered from use of the automated PDPS technology platform. In addition, PeptiDream is eligible to receive royalties on sales of certain products that arise from use of the automated PDPS technology platform. Similar to previous technology license agreements, work on peptide-drug conjugates (PDCs) is excluded from the non-exclusive license.

High-affinity peptides will be identified through the use of the automated PDPS technology platform for new drug targets that have been suggested to be associated with specific diseases. ONO will also leverage the information obtained through the process, aiming to discover and develop innovative new drugs in a short period of time with high success rate.

*“We are very much pleased by ONO’s decision to adopt our automated PDPS platform, which we believe is a fruit of their appreciation of the value of PeptiDream’s macrocyclic/constrained peptide screening technology. With the automated PDPS platform, we are confident that ONO’s drug discovery and research efforts will be greatly accelerated, which will contribute to further advance the development of new therapeutics. We look forward to working with and supporting ONO not only through the automated PDPS platform and supplies of reagents but on all aspects related to our PDPS technology.”* said **Keiichi Masuya PhD, Executive Vice President of PeptiDream.**

*“We highly appreciate PeptiDream’s automated PDPS technology platform. By using this platform, we will further enhance our corporate value by delivering innovative new products*

*that meet unmet medical needs to patients as early as possible.” said **Toichi Takino, Ph.D., Member of the Board of Directors, Executive Officer and Executive Director, Discovery and Research of ONO.***

**<About PeptiDream Inc.>**

PeptiDream Inc. is a public (Tokyo Stock Exchange 1<sup>st</sup> Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit [www.peptidream.com](http://www.peptidream.com).

**Enquiries:**

**PeptiDream Inc.**

Mie Yamazaki IR & Public Affairs - (Kanagawa)

EMAIL: [m-yamazaki@peptidream.com](mailto:m-yamazaki@peptidream.com)